Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs UnitedHealth Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while UnitedHealth Group Inc trades at $428.89 (market cap $385.62B). The key difference: UnitedHealth Group Inc is far larger — about 9.7× Alnylam Pharmaceuticals, Inc.'s market cap, and UnitedHealth Group Inc pays a 2.19% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UNH | |
|---|---|---|
Market Cap | $39.89B | $385.62B |
Sector | Health | Health |
52-Week High | $491.22 | $431.68 |
52-Week Low | $278.09 | $237.77 |
Enterprise Value | $38.15B | $432.30B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
UnitedHealth Group (UNH) trades at $424.62, down 1.64% on the day, slightly above the analyst consensus price target of $423.18. The stock shows bullish technical signals with strong moving average support and recent earnings beats in three consecutive quarters. Revenue has grown consistently from $322.1B in 2022 to $447.6B in 2025, though net income margin has compressed from 6.24% to 2.69% over the same period. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns through dividends and buybacks.
Outlook remains positive with 82.7% analyst buy ratings and strong institutional support, driven by aging demographics and healthcare innovation. Key risks include regulatory scrutiny (Massachusetts Medicaid lawsuit filed May 29, 2026), margin pressure from rising costs, and increasing debt levels. The current P/E of 31.97 appears elevated relative to historical norms, suggesting valuation sensitivity to earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
